Nystatin Unsuitable for Invasive Candidiasis in Neutropenic Patients

The question asks to identify the drug not recommended for treating invasive candidiasis specifically in neutropenic patients. Neutropenic patients have a very low white blood cell count, making them highly susceptible to severe infections.

Understanding Antifungal Therapy Choices

For invasive fungal infections like invasive candidiasis, the chosen antifungal must be effective systemically (throughout the body). Let's analyze the options:

• Amphotericin-B: A potent antifungal agent effective against a broad spectrum of fungi, including Candida species. It is commonly used for invasive candidiasis.
• Caspofungin: An echinocandin antifungal drug. It disrupts the fungal cell wall and is a recommended treatment option for invasive candidiasis, including in neutropenic patients.
• Voriconazole: A broad-spectrum triazole antifungal. It is effective systemically and is a key treatment option for various invasive fungal infections, including invasive candidiasis.
• Nystatin: This antifungal is primarily used topically for superficial Candida infections (e.g., oral thrush, vaginal candidiasis). It has very poor gastrointestinal absorption and is not suitable for treating systemic or invasive infections.

Rationale for Nystatin Exclusion

Nystatin's lack of systemic absorption means it cannot reach the site of an invasive infection within the body. Therefore, it is ineffective and not recommended for treating invasive candidiasis, particularly in vulnerable neutropenic patients who require aggressive systemic therapy.

The recommended treatments for invasive candidiasis in neutropenic patients are systemic antifungals like Amphotericin-B, Caspofungin, or Voriconazole, depending on the specific situation and susceptibility patterns.